The FDA has cleared HuidaGene Therapeutics' investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter...

A new CRISPR-dCas13 tool developed by French researchers modulates alternative splicing without altering gene expression. The RNA-editing system,...

In an article just published in Science, researchers at University of California Berkeley, Gladstone Institutes (San Francisco) and Lawrence Berkeley...